Renovaro Biosciences Inc Cash Flow Conversion Efficiency
Renovaro Biosciences Inc cash flow conversion efficiency. Based on the latest financial reports, Renovaro Biosciences Inc (RENB) has a cash flow conversion efficiency ratio of 0.085x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.81 Million) by net assets ($-21.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Renovaro Biosciences Inc (2012–2025)
Cash flow conversion efficiency of Renovaro Biosciences Inc from 2012 to 2025. This chart illustrates how Renovaro Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Renovaro Biosciences Inc stock price for real-time trading data and today's change.
Renovaro Biosciences Inc Cash Flow Conversion Ratio Explained
Renovaro Biosciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Renovaro Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Renovaro Biosciences Inc ranked by their cash flow conversion efficiency. Also see market cap of Renovaro Biosciences Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HOYA Resort Hotel Group
TWO:2736
|
0.038x |
|
Visi Media Asia Tbk
JK:VIVA
|
0.067x |
|
Hansol Pns
KO:010420
|
0.036x |
|
Thai Film Industries Public Company Limited
BK:TFI
|
-0.010x |
|
Starteck Finance Limited
NSE:STARTECK
|
0.044x |
|
M.K. Real Estate Development Public Company Limited
BK:MK
|
0.037x |
|
Thai O.P.P. Public Company Limited
BK:TOPP
|
0.030x |
|
Megachem (Thailand) Public Company Limited
BK:MGT
|
0.034x |
Annual Cash Flow Conversion Efficiency for Renovaro Biosciences Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Renovaro Biosciences Inc from 2012 to 2025. Review RENB financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $131.98 Million | $-10.97 Million | -0.083x | 0.00% |
| 2024-06-30 | $131.98 Million | $-10.97 Million | -0.083x | +67.17% |
| 2023-06-30 | $46.50 Million | $-11.77 Million | -0.253x | -16.88% |
| 2022-06-30 | $72.62 Million | $-15.73 Million | -0.217x | -83.59% |
| 2021-06-30 | $174.66 Million | $-20.61 Million | -0.118x | -87.59% |
| 2020-06-30 | $166.27 Million | $-10.46 Million | -0.063x | -27.99% |
| 2019-06-30 | $173.10 Million | $-8.51 Million | -0.049x | -79.83% |
| 2018-06-30 | $158.74 Million | $-4.34 Million | -0.027x | +96.44% |
| 2017-06-30 | $1.53 Million | $-1.18 Million | -0.768x | -133.26% |
| 2016-06-30 | $-637.40K | $-1.47 Million | 2.310x | +495.42% |
| 2015-06-30 | $3.48 Million | $-2.03 Million | -0.584x | -143.88% |
| 2014-06-30 | $-1.60 Million | $-2.13 Million | 1.331x | +126.81% |
| 2013-06-30 | $-51.27K | $-30.09K | 0.587x | -67.81% |
| 2012-06-30 | $-13.68K | $-24.95K | 1.823x | -- |
About Renovaro Biosciences Inc
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors… Read more